Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty

The use of abciximab after full-dose failed thrombolytics within 15 hours of acute myocardial infarction significantly increases the risk of major bleeding complications.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 1999-06, Vol.83 (11), p.1569-1570
Hauptverfasser:	Sundlof, Deborah W, Rerkpattanapitat, Pairoj, Wongpraparut, Nattawut, Pathi, Padmavathi, Kotler, Morris N, Jacobs, Larry E, Ledley, Gary S, Yazdanfar, Shahriar
Format:	Artikel
Sprache:	eng
Schlagworte:	Abciximab Aged Angioplasty Angioplasty, Balloon, Coronary Antibodies, Monoclonal - adverse effects Cardiology Female Hemorrhage - epidemiology Hemorrhage - etiology Humans Immunoglobulin Fab Fragments - adverse effects Incidence Male Medical procedures Medical research Middle Aged Myocardial Infarction - drug therapy Myocardial Infarction - therapy Platelet Aggregation Inhibitors - adverse effects Retrospective Studies Thrombolytic Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!